Health News Roundup: Bayer Launches Asundexian Phase III Study Program; Abbott restarts production of Similac infant formula at its Michigan plant and more

Here is a summary of health news briefs.

Abbott restarts production of Similac infant formula at its Michigan plant

Abbott Laboratories has restarted production of its Similac infant formula at the Sturgis, Michigan plant at the center of the U.S. infant formula shortage. Abbott, the largest U.S. infant formula supplier, in February recalled Similac and other infant formulas produced at the Michigan plant after reports of bacterial infections in babies who had consumed products made from it.

In the United States, very few people receive a full series of monkeypox vaccines, says CDC chief

Very few people who have been vaccinated against monkeypox in the United States have received the second dose needed for full protection, U.S. Centers for Disease Control and Prevention (CDC) director Rochelle Walensky said on Friday. . She told a White House briefing that almost 97% of injections given were first doses, and while many people are eligible for a second dose, “very few” have been given so far.

Bayer launches asundexian phase III study program

Germany’s Bayer announced on Sunday that it is launching a phase III study program to study the efficacy and safety of asundexian, an oral factor XIa (FXIa) inhibitor. The drug candidate is a potential new treatment for patients with atrial fibrillation and in patients with non-cardioembolic ischemic stroke or high-risk transient ischemic attack, Bayer said.

AstraZeneca’s Farxiga reduces risk of death in heart failure patients – study

AstraZeneca’s flagship diabetes drug Farxiga has led to significant reductions in the risk of hospitalization and death in people with all types of heart failure, according to study data released on Saturday, opening the door to a substantial increase in the number of patients who could benefit from it. The drug belongs to a class of drugs called SGLT2 inhibitors that were originally approved to treat type 2 diabetes. Since then, the drugs have been shown to benefit patients with chronic kidney and heart disease and prevent heart disease. heart attack.

(With agency contributions.)

Ryan H. Bowman